FeesSafety
Pluang+

FDA agrees to Annovis' plan to pool Alzheimer’s and Parkinson’s safety data for buntanetap NDA

Market News
20 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
FDA agrees to Annovis' plan to pool Alzheimer’s and Parkinson’s safety data for buntanetap NDA

Annovis Bio received FDA agreement on its plan to combine safety data from four clinical studies on buntanetap, targeting Alzheimer’s and Parkinson’s diseases. This integrated safety summary will support their New Drug Application (NDA) planned after the DUET-AD Phase 3 study data readout. Pooling data from both diseases leverages the drug’s common action mechanism, creating a robust safety database with over 1,600 participants. FDA’s agreement facilitates NDA preparation but does not guarantee approval, which depends on full review of efficacy and safety results.

Annovis Bio's FDA agreement on an integrated safety summary for buntanetap provides context for the health sector's market activity. For readers following the health sector, here is Pluang's market snapshot as of Nov 20, 2026 19:11 WIB: out of 150 priced US health stocks tradable on Pluang, 72 rose and 71 fell. Notable movers include Humana Inc (HUM) at USD 389.50 with a 1-day change of +2.50% and a typical hold time of 52 days, Summit Therapeutics Inc (SMMT) at USD 10.31 down 2.46%, and Hims and Hers Health Inc (HIMS) at USD 15.64 down 2.37%.

More News

TREMFYA shows significant improvement in spinal pain and inflammation in psoriatic arthritis patients in Phase 4 study

TREMFYA shows significant improvement in spinal pain and inflammation in psoriatic arthritis patients in Phase 4 study

Johnson & Johnson's TREMFYA (guselkumab) demonstrated significant improvements in spinal pain, stiffness, and MRI-confirmed inflammation in patients with axial psoriatic arthritis (PsA) in the Phase 4 STAR study. The study, the first of its kind usin...

Company Fundamentals
Bullish
48 minutes ago
Build a balanced portfolio with Vanguard Morningstar Growth ETF for growth and Schwab U.S. Dividend Equity ETF for income.

Build a balanced portfolio with Vanguard Morningstar Growth ETF for growth and Schwab U.S. Dividend Equity ETF for income.

Investors seeking both growth and income can consider a simple ETF portfolio combining the Vanguard Morningstar Growth ETF (VUG) and the Schwab U.S. Dividend Equity ETF (SCHD). VUG focuses on large-cap growth stocks, heavily weighted in technology, w...

Market News
Bullish
1 hour ago
Hyperliquid aims to become the Amazon of decentralized finance by scaling perpetual futures markets.

Hyperliquid aims to become the Amazon of decentralized finance by scaling perpetual futures markets.

Hyperliquid, a decentralized exchange specializing in perpetual futures contracts, is expanding its platform to include real-world assets and prediction markets, aiming to become the "house all of finance." It operates similarly to Amazon's marketpla...

Market News
Bullish
1 hour ago
Bitcoin plunges below $62,000 amid tech selloff, inflation fears, and largest crypto hack ever.

Bitcoin plunges below $62,000 amid tech selloff, inflation fears, and largest crypto hack ever.

Bitcoin has dropped below $62,000 after six consecutive weeks of decline, falling more than 50% from its October 2025 peak of around $126,000. The slide was triggered by a combination of factors including a tech sector selloff due to AI valuation con...

Bearish
1 hour ago
Rocket Lab beats sales estimates, backlog soars, and posts first positive operating cash flow quarter.

Rocket Lab beats sales estimates, backlog soars, and posts first positive operating cash flow quarter.

Rocket Lab reported Q3 sales of $268 million, beating estimates and marking a 73% year-over-year increase, with a backlog growing to $3.6 billion. Despite missing earnings expectations with a loss of $0.12 per share, the company achieved its first fu...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App